CVS Health Corp.’s pharmacy benefit management (PBM) unit is launching a new program under which employers and insurers will be able to offer diabetes drugs, including insulin, at no out-of-pocket costs to their members.

The pharmaceutical industry’s greatest value lies in the quality of life that its drugs provide – plus the innovative programs that help support adherence and education.

U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation aimed at lowering the cost of prescription drugs for U.S. consumers.

Pharmacy chain CVS Health Corp. won U.S. antitrust approval for the $69 billion acquisition of health insurer Aetna Inc., the Justice Department said.

Amgen Inc.’s push to get patients on its new $575 a month migraine drug before competition emerges in September 2018 is facing barriers from insurers.

With two major prescription drug supply deals announced within a four-month period, the landscape of pharmacy benefits management is changing dramatically.

As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.

Goldman Sachs published a 30-page report on how Amazon could break into the prescription drug market. Written by five analysts, the report points out that although Amazon has not explicitly stated it is interested in entering the prescription drug market, it has developed the secretive 1492 group, which is reportedly working on medical devices, and hired Missy Krasner, former vice president and managing director of Box’s healthcare and life sciences group to head up its pharmacy group. Box markets cloud management products and services.

Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.

U.S. pharmacy benefit manager CVS will drop Sanofi’s main insulin drug Lantus from the list of medicines it reimburses on behalf of health insurers.